

Frank Henrichsen Appointed Director of Global Sales at Nanion Technologies

Munich, Germany, January 13, 2016; Nanion Technologies is pleased to announce that Frank Henrichsen has accepted the position of Director of Global Sales. Frank Henrichsen has a solid technical and commercial track record in life science industry, and is one of the pioneers in the global deployment of automated patch clamp systems in pharmaceutical companies and CROs.

Following the successful roll-out of the SyncroPatch 384/768PE, an advanced ion channel high throughput screening platform, Nanion is with the appointment of Frank Henrichsen as Global Sales Director, dedicated to further strengthening sales and customer support in the life science industry. During Henrichsen's assignment as Vice President of Sales and Marketing at Sophion Bioscience, he was instrumental in building the company's distribution network and customer base. Henrichsen's extensive experience with sales management and automated patch clamping combined with his large network in the pharmaceutical industry make him ideally suited to further accelerate Nanion's commercial success.

Dr. Niels Fertig, CEO of Nanion Technologies, says:

"Frank is not only a very dedicated and experienced professional with a profound background in technology commercialization, but also an expert in the automated patch clamp instrumentation business. He knows about ion channel screening from a customer requirement perspective, and how to meet and support customers! This combination together with his great personality makes him the ideal person to enhance Nanion's commercial growth. During his tenure at Sophion, we at Nanion always respected his work tremendously, while at the same time appreciated his fair and sporty competition. I am delighted to welcome Frank on the team!"

Frank Henrichsen continues:

"I have followed Nanion closely since the company emerged in 2002. The Nanion team members have always impressed me with their dedication to science, their strength in rapid and continuous technical innovation and entrepreneurship and – not less – their always open and friendly attitude. In times where organizational changes, mergers and acquisitions are almost daily events, Nanion has demonstrated an unsurpassed organizational stability. It is easy to see how such stability can be transferred into intensified customer focus and continued product innovation. I really look forward to assist Nanion in further strengthening their commercial success while maintaining the company's unique culture."

About Nanion

Nanion Technologies was founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS). Over the last 14 years it has grown to a strong company with over 80 employees worldwide. Nanion has its headquarters in Munich, Germany, and has daughter companies in the USA, Japan and China, with distribution partners in 7 other countries. Nanion has been recognized for its quality and innovation by being twice nominated for the Federal President's Award for Technology and Innovation (Deutscher Zukunftspreis) in 2007 and 2014. The company has become known for its high quality instruments for ion channel research (Port-a-Patch, Patchliner and SyncroPatch product families) and has over the years expanded its product range to include cardiotoxicity screening (CardioExcyte 96), parallel bilayer recordings (Orbit 16), and parallel membrane transporter protein recordings (SURFE2R). Since 2014, Nanion carries Axion's multi-electrode array (MEA) systems in Europe and China.